Search
On September 22, 2025, Maiwei Biological, Insilico Medicine, and Haoyuan Pharmaceutical unveiled a strategic cooperation agreement. These three entities will pool their unique strengths in the realms of biological drug discovery, AI-driven drug design, chemical synthesis, and process development. Their collective aim is to jointly construct a cutting-edge ADC (Antibody-Drug Conjugate) compound library encompassing hundreds of targets. Through this collaboration, they will meticulously screen and develop next-generation ADC candidate molecules, with the ultimate goal of expediting the industrialization of innovative ADC drugs. This strategic move underscores the increasing trend of cross-industry collaboration in the pharmaceutical sector, where companies leverage each other's expertise to drive innovation and bring life-saving drugs to market faster.
-
C114 Communication Network -
Communication Home
